Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock.
ESSA Pharma Inc. (EPIX) is a clinical-stage biotechnology company that pioneered research into novel prostate cancer therapies targeting androgen receptor signaling. This page provides investors and industry observers with timely updates on corporate developments, including strategic reviews and historical clinical trial data.
Access verified press releases, financial filings, and official statements related to EPIX's discontinued clinical programs and ongoing business evaluations. Our curated news collection ensures efficient tracking of key milestones in the company's transition from active drug development to strategic repositioning.
Content includes updates on partnership opportunities, regulatory communications, and analyses of EPIX's specialized approach to oncology research. Bookmark this page for direct access to primary source materials and unfiltered corporate announcements, maintained for both professional investors and research stakeholders.
ESSA Pharma (NASDAQ: EPIX), a clinical-stage pharmaceutical company aimed at developing innovative prostate cancer treatments, announced its participation in the JonesHealthcare Seaside Summit. The event will take place on July 15, 2024, at 11:00 a.m. PT. The company's President and CEO, David R. Parkinson, will lead the presentation and join a panel discussion titled 'Innovations and Challenges in Prostate Cancer' at 9:00 a.m. PT. The presentation will be webcast live on the Investors/Events & Presentations section of the ESSA Pharma website and will remain archived for 90 days post-event. However, the panel discussion will not be available via webcast.
ESSA Pharma (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for prostate cancer, announced it will present at the Jefferies Global Healthcare Conference on June 6, 2024, at 12:30 p.m. ET in New York.
Company executives David R. Parkinson (President & CEO) and David S. Wood (CFO) will host and participate in one-on-one meetings.
The event will be webcast live and available on the ESSA website for 90 days.
ESSA Pharma (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on prostate cancer therapies, reported its financial results for the second fiscal quarter ending March 31, 2024. Highlights include the promising Phase 1 data for masofaniten plus enzalutamide, showing a deep and durable reduction in PSA levels among mCRPC patients. Key achievements include 81% of patients achieving PSA90. ESSA forecasts the completion of Phase 2 enrollment by 1Q25, with preliminary data expected in mid-2025. Financially, ESSA experienced a net loss of $9.0 million, up from $7.1 million the previous year, due to increased R&D and G&A expenses. The company holds $135.9 million in cash reserves, enough to fund operations beyond 2025.
FAQ
What is the current stock price of Essa Pharma (EPIX)?
What is the market cap of Essa Pharma (EPIX)?
